MANGOCEUTICALS, INC. Income Statement
MGRX|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$456,021
FY2025
Gross Profit
$250,386
54.9% gross margin
Operating Income
-$18M
FY2025
Net Income
-$21M
FY2025
MANGOCEUTICALS, INC. reported $456,021 in revenue and $21M in net loss for FY2025. Revenue has grown at a 614.2% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $456.0K | $731.5K | $8.9K |
| Cost of Revenue | $54.4K | $154.9K | $4.1K |
| Gross Profit | $250.4K | $431.5K | $4.8K |
| SG&A Expense | $3.8M | $3.3M | $1.6M |
| Operating Income | -$18.0M | -$9.2M | -$2.0M |
| Interest Expense | - | -$6.5K | $6.5K |
| Net Income | -$20.6M | -$9.2M | -$2.0M |
| EPS (Basic) | -$4.80 | -$8.58 | -$0.19 |
| EPS (Diluted) | -$4.80 | -$8.58 | -$0.19 |
| Shares Outstanding | 32.0M | 1.4M | 13.4M |
| Gross Margin | 54.9% | 59.0% | 54.3% |
| Operating Margin | -3954.3% | -1260.3% | -22279.7% |
| Profit Margin | -4526.8% | -1259.4% | -22352.1% |